Favezelimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Favezelimab
- anti lag3 monoclonal antibody mk 4280
- ANTI-LAG3 MONOCLONAL ANTIBODY MK-4280
- favezelimab
- Favezelimab
- favezelimab [INN]
- FAVEZELIMAB [USAN]
- Favezelimab [WHO-DD]
- favezelimab inn
- favezelimab usan
- favezelimab who dd
- Immunoglobulin G4 [227-proline], anti-(human lymphocyte activation gene-3) (human-Mus musculus monoclonal C88 γ4-chain), disulfide with human-Mus musculus monoclonal C88 κ-chain, dimer
- immunoglobulin g4 227 proline anti human lymphocyte activation gene 3 human mus musculus monoclonal c88 γ4 chain disulfide with human mus musculus monoclonal c88 κ chain dimer
- immunoglobulin g4 kappa anti homo sapiens lag3 lymphocyte activating 3 lymphocyte activation 3 cd223 humanized monoclonal antibody gamma4 heavy chain humanized 1 446 vh homo sapiens ighv1 58 01 85 6 ighd ighj1 01 91 7 8 8 12 1 119 homo sapiens ighg4 01 ch1 120 217 hinge 1 12 218 229 ch2 230 339 ch3 340 444 chs 445 446 120 446 133 218 disulfide with kappa light chain humanized 1 218 v kappa homo sapiens igkv2d 29 01 82 0 igkj4 01 100 10 3 9 1 111 homo sapiens igkc 01 100 km3 a45 1 157 v101 195 112 218 dimer 225 225 228 228 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- Immunoglobulin G4-kappa, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-446) [VH (Homo sapiens IGHV1-58*01 (85.6%) -(IGHD) -IGHJ1*01 (91.7%)) [8.8.12] (1-119) -Homo sapiens IGHG4*01 (CH1 (120-217), hinge 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133- 218')-disulfide with kappa light chain humanized (1'- 218') [V-KAPPA (Homo sapiens IGKV2D-29*01 (82.0%) -IGKJ4*01 (100%))[10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- mavezelimab
- Mavezelimab
- mk 4280
- Mk-4280
- MK-4280
- mk4280
- MK4280
- CAS registry numbers
- 2231068-83-8
- ChEMBL ID
- CHEMBL4297784
- FDA ingredient codes (UNII)
- H1396W7D1H
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Lymphocyte activation gene 3 protein inhibitor
- Action type
- Inhibitor
- Target
- Lymphocyte activation gene 3 protein
- Protein identifier
- P18627
Open Targets mechanisms
- Mechanism
- Lymphocyte activation gene 3 protein inhibitor
- Action type
- Inhibitor
- Target
- Lymphocyte activation gene 3 protein
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Neoplasm Metastasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009708
- Subject identifier
- D009362
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005952
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001927
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004703
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007576
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009348
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0040679
- Highest recorded phase
- 1
- NCT02625961
- NCT02720068
- NCT03516981
- NCT03598608
- NCT05508867
- NCT04303169
- NCT04305054
- NCT04626479
- NCT04626518
- NCT04895722
- NCT05064059
- NCT05600309
- NCT04938817
- NCT05342636
- NCT05845814
- NCT06395090
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-92' $ 23'''-92''' $ 146-202 $ 146''-202'' $ 133-218' $ 133''-218''' $ 138'-198' $ 138'''-198''' $ 225-225'' $ 228-228'' $ 320-260 $ 320''-260'' $ 366-424 $ 366''-424''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 296 $ 296''
Related records
Trials (18)
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
In development for (12)
- Colorectal cancer Phase 3
- Esophageal squamous cell carcinoma Phase 1
- Hodgkins lymphoma Phase 3
- Lymphoma Phase 1
- Melanoma Phase 1
- Neoplasm Phase 1
- Non-Hodgkin lymphoma Phase 1
- Non-small cell lung carcinoma Phase 2
- Renal cell carcinoma Phase 1
- Small cell lung carcinoma Phase 1
- Urinary bladder cancer Phase 2
- Urothelial carcinoma Phase 2
Targets (1)
- LAG3 Lymphocyte activation gene 3 protein inhibitor